| 초록 |
Despite the numbers of commercial products are available on the market in recent years since first injectable bone substitutes came into light, there is still a necessity to improvise the characteristics and biocompatibility of the injectable bone system. In this current study, we focused on the modification of brushite (dicalcium phosphate dihydrate, DCPD) cement as injectable bone substitute with platelet-rich plasma (PRP) for improved biocompatibility and bone regeneration in vivo. For comparison, two groups of brushite cement were analysed. One group was made of β-tricalcium phosphate (β-TCP), monocalcium phosphate monohydrate (MCPM) and citrate ion mixing aqueous solution, and the other group consisted of addition of PRP as liquid phase in the same composition. By incorporating PRP into cement, cohesion time and setting time decreased but no significant effect on compressive strength. However the cement injectability and viscosity were improved significantly. In vitro degradation and activity were evaluated with the scanning electron microscope (SEM) image and XRD profile which indicated that in case of modified cement with PRP, the growth of chemical phase of the cement and conversion of DCPD and bone appetite formation delayed. In vitro cell adhesion and proliferation were also evaluated by SEM, MTT, and F-actin assay. By adding PRP, cyto-compatibility was improved and cells effectively adhered, spread, and proliferated. In vivo performance was evaluated in rabbit femur head. After implantation 1 and 2 months, samples were extracted and evaluated by micro-CT analysis, hematoxylin and eosin (H&E) and Masson's trichrome staining. Our result demonstrated that incorporation of PRP in brushite cement improved biocompatibility and bone in-growth. |
